CPRX Earnings Prediction
The chart below shows how CPRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CPRX sees a +1.04% change in stock price 10 days leading up to the earnings, and a +9.76% change 10 days following the report. On the earnings day itself, the stock moves by -0.83%. This data can give you a slight idea of what to expect for the next quarter's release.
CPRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
141.82M
28.26%
10.20%
Gross Margin
78.15%
0.83%
0.50%
Operating Margin
44.31%
17.50%
12.01%
Net Margin
39.44%
25.17%
15.66%
EPS
0.44
41.94%
25.71%
No Data Available
CPRX Earnings Analysis
Catalyst Pharmaceuticals Inc Corporation (CPRX.O) Earnings Conference Call
Positive
Revenue Growth Exceeds Guidance: Total revenues grew by 23.5% year-over-year to $491.7 million, exceeding previous guidance.
Product Revenue Surge: Full-year net product revenue reached $489.3 million, a 23.4% increase over 2023, driven by the successful launch of AGAMREE.
Record Revenue Increase: Q4 2024 total revenues reached a record $141.8 million, an increase of 28.3% over Q4 2023, driven by organic growth of FIRDAPSE and contributions from AGAMREE.
Sustained Growth Momentum: FIRDAPSE showed sustained momentum with 14 consecutive quarters of 15% or more growth year-over-year, indicating strong market demand.
Product Adoption Success: AGAMREE gained significant traction since its launch, with strong adoption in DMD Centers of Excellence and a successful commercial launch.
Patent Litigation Resolution: The favorable resolution of the Teva patent litigation reinforces FIRDAPSE's intellectual property strength, prohibiting generic entry until February 2035.
Strong Cash Position: The company ended the year with a robust cash position of $517.6 million and no debt, enhancing capacity for strategic growth investments.
Field Force Growth Strategy: The dedicated field force for FIRDAPSE and AGAMREE is expected to drive deeper adoption and continued growth in 2025.
Rare Disease Opportunities Evaluation: The company is actively evaluating accretive rare disease opportunities to drive sustainable success and long-term growth.
High Approval Rates: FIRDAPSE's approval rates exceeded 90% for all types of payers, showcasing strong market acceptance and patient access.
Negative
Revenue Decline Forecast: FYCOMPA is expected to experience a gradual revenue decline in the second half of 2025 due to anticipated generic competition and the loss of exclusivity in May 2025.
Gross to Net Deductions Impact: The company faced an increase in gross to net deductions for FYCOMPA, which negatively impacted net product revenue compared to 2023.
Adoption Delays Impact Growth: AGAMREE's adoption may face delays due to a queuing effect for patients being evaluated for treatment, potentially hindering immediate growth.
AGAMREE Royalties Impact: The company anticipates increased AGAMREE royalties as a percentage of net sales in 2025, which could affect profitability.
Rising SG&A Expenses: SG&A expenses increased significantly in 2024, and are expected to rise further in 2025 due to increased headcount and support for expanding infrastructure.
Tax Rate Consistency and Uncertainty: The effective tax rate is expected to remain consistent, but could fluctuate based on various factors, adding uncertainty to future financial performance.
CPRX FAQs
How does CPRX typically perform around its earnings report dates?
Is Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CPRX Earning Call Sentiment
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript
CPRX.O
1.34%Positive
The earnings call highlighted strong financial performance with a 23.5% YoY revenue increase and exceeding revenue guidance for AGAMREE. The company also announced a share repurchase program, which typically has a positive impact on stock prices. While there are some concerns, such as the slight decrease in FYCOMPA revenue and unclear SG&A guidance, the overall sentiment remains positive, particularly with the raised guidance for AGAMREE and lower R&D expenses. Given the market cap of approximately $1.78 billion, the stock is likely to see a positive price movement.
